KYORIN Pharmaceutical Co., Ltd. Logo

KYORIN Pharmaceutical Co., Ltd.

A research-based pharmaceutical company that develops and sells prescription and generic drugs.

4569 | T

Overview

Corporate Details

ISIN(s):
JP3247090008
LEI:
Country:
Japan
Address:
千代田区大手町一丁目3番7号

Description

KYORIN Pharmaceutical Co., Ltd. is a research-based pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription (ethical) and generic drugs. The company's commercial and R&D activities are focused on key therapeutic areas, including respiratory medicine, urology, otolaryngology (ENT), and inflammatory bowel disease (IBD). Through its subsidiaries, such as KYORIN Rimedio Co., Ltd., it also handles the manufacturing and distribution of generic medicines. The company is committed to providing a stable supply of high-quality pharmaceutical products to medical institutions and patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2018-11-14 07:00
四半期報告書-第61期第2四半期(2018/07/01-2018/09/30)
Japanese 196.6 KB
2018-08-10 07:59
四半期報告書-第61期第1四半期(2018/04/01-2018/06/30)
Japanese 170.5 KB
2018-06-25 07:31
有価証券報告書-第60期(平成29年4月1日-平成30年3月31日)
Japanese 1.1 MB
2018-02-14 06:53
四半期報告書-第60期第3四半期(2017/10/01-2017/12/31)
Japanese 152.7 KB
2017-11-14 07:00
四半期報告書-第60期第2四半期(2017/07/01-2017/09/30)
Japanese 180.5 KB
2017-08-10 08:01
四半期報告書-第60期第1四半期(2017/04/01-2017/06/30)
Japanese 149.0 KB
2017-06-26 07:49
有価証券報告書-第59期(2016/04/01-2017/03/31)
Japanese 1.1 MB
2017-02-14 06:15
四半期報告書-第59期第3四半期(2016/10/01-2016/12/31)
Japanese 159.7 KB
2016-11-14 05:44
四半期報告書-第59期第2四半期(2016/07/01-2016/09/30)
Japanese 182.5 KB
2016-08-10 07:27
四半期報告書-第59期第1四半期(2016/04/01-2016/06/30)
Japanese 150.3 KB
2016-06-27 07:25
有価証券報告書-第58期(2015/04/01-2016/03/31)
Japanese 1.2 MB
2016-02-12 05:44
四半期報告書-第58期第3四半期(2015/10/01-2015/12/31)
Japanese 158.3 KB
2015-11-13 06:38
四半期報告書-第58期第2四半期(2015/07/01-2015/09/30)
Japanese 181.8 KB

Automate Your Workflow. Get a real-time feed of all KYORIN Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYORIN Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYORIN Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.